Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 2/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | ALPI | P09923 | 1/20 | 0.30 |
| ▸ | ALPG | P10696 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407512 | 0.92 | KDM4E (0.38) | KDM4EKMT2ANFE2L2BACE1PARP1 | |
| SCHEMBL1671574 | 0.76 | — | — | |
| SCHEMBL2300942 | 0.75 | NQO2 (0.42) | KDM4EBACE1PARP1ALDH1A1MAPT | |
| SCHEMBL405980 | 0.75 | F7 (0.42) | KDM4EKMT2APARP1ALDH1A1MEN1 | |
| SCHEMBL7040872 | 0.72 | ALDH1A1 (0.48) | KDM4EKMT2ANFE2L2ALDH1A1PDGFRB | |
| SCHEMBL2306818 | 0.71 | SCN10A (0.36) | KDM4EKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL29551059 | 0.70 | KMT2A (0.52) | KDM4EKMT2ABACE1PARP1GFER | |
| SCHEMBL622743 | 0.70 | KMT2A (0.52) | KDM4EKMT2ABACE1PARP1GFER | |
| SCHEMBL9956541 | 0.69 | — | — | |
| SCHEMBL9955749 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | claimed |
| EP-4100410-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| CN-115362156-A | Muscarinic receptor 4 antagonists and methods of use | 纽罗克里生物科学有限公司 | 2022-11-18 | — | — | CN | claimed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | claimed |
| EP-2389066-B1 | CYCLOPENTADIONE DERIVED HERBICIDES | SYNGENTA LTD (GB) | 2017-07-05 | — | — | EP | claimed |
| EP-2387569-B1 | HERBCIDES | SYNGENTA LTD (GB) | 2016-06-15 | — | — | EP | claimed |
| US-8895474-B2 | Herbicidally active cyclopentanediones and derivatives thereof, and their use in controlling weeds | SYNGENTA LIMITED (GB) | 2014-11-25 | — | — | US | claimed |
| US-8865623-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds | SYNGENTA LIMITED (GB) | 2014-10-21 | — | — | US | claimed |
| WO-2013050938-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-11 | — | — | WO | claimed |
| WO-2012085852-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | claimed |
| EP-0148119-B1 | AMIDES OF 2-PHENOXYPROPIONIC ACID | CIBA-GEIGY AG (CH) | 1989-05-03 | — | — | EP | claimed |
| US-4640703-A | CONTROLLING GRASSES IN CROPS | CIBA-GEIGY CORPORATION (US) | 1987-02-03 | — | — | US | claimed |
| CN-86103114-A | The halogenated alkoxy benzene of 2-(4-heterocyclic oxy group phenoxy group) alkanoic acid is for the preparation of amide derivatives and as herbicide applications | — | 1986-12-17 | — | — | CN | claimed |
| EP-0148119-A2 | Amides of 2-phenoxypropionic acid | CIBA-GEIGY AG (CH) | 1985-07-10 | — | — | EP | claimed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| EP-4100410-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115362156-A | Muscarinic receptor 4 antagonists and methods of use | 纽罗克里生物科学有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-86103114-A | The halogenated alkoxy benzene of 2-(4-heterocyclic oxy group phenoxy group) alkanoic acid is for the preparation of amide derivatives and as herbicide applications | — | 1986-12-17 | — | — | CN | disclosed |
| US-4601748-A | 2-phenoxy propionic acid derivatives of pentite, process for the production of these compounds as well as compositions containing the same having herbicidal effectiveness | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-07-22 | — | — | US | disclosed |
| EP-0148119-A2 | Amides of 2-phenoxypropionic acid | CIBA-GEIGY AG (CH) | 1985-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | KDM4E 2192/4885KMT2A 1920/4885NFE2L2 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.